4 published verifications about CYP2C19 CYP2C19 ×
“The CYP2C19 gene has high genetic variability, with 39 possible alleles that influence the rate of medication metabolism.”
Evidence from NHS England and peer-reviewed pharmacogenomics reviews supports that CYP2C19 is highly variable and that 39 identified or characterized alleles/haplotypes have been linked to differences in drug metabolism. The main caveat is wording: these are catalogued variants from a specific time point, not all theoretically possible alleles, and the count can change as databases are updated.
“The human enzyme CYP2C19 metabolizes about 10% of commonly prescribed medications, including some antidepressants, proton pump inhibitors, clopidogrel, and voriconazole.”
Reliable medical references support the statement that CYP2C19 is involved in metabolizing about 10% of commonly prescribed drugs. The cited examples—some antidepressants, proton pump inhibitors, clopidogrel, and voriconazole—are all well-established CYP2C19-related medications. The exact percentage can vary by source and definition, but that caveat does not change the main takeaway.
“Scientific studies report an association between CYP2C19 genetic variants and major depressive disorder, longer depressive episodes, and greater depressive symptom severity.”
Published studies do report these associations. Systematic reviews and several primary studies describe links between CYP2C19 variants and depression risk, longer episodes, or greater symptom severity, even though results are mixed overall. The claim stays within what the evidence supports because it says studies report an association, not that the association is proven or universal.
“CYP2C19 genetic variants that reduce CYP2C19 enzyme activity can contribute to relatively treatment-resistant depression by reducing the metabolism of some antidepressants.”
Reduced-function CYP2C19 variants do decrease metabolism of some antidepressants, particularly several SSRIs. That can contribute to failed treatment in practice by raising drug levels, increasing side effects, and prompting nonadherence or discontinuation. However, the evidence does not clearly show that reduced CYP2C19 activity directly makes these antidepressants less effective; the main risk is apparent resistance from poor tolerability.